Edgewise Therapeutics Reports Second Quarter 2023 Financial

– Announced positive 12-month topline results from the ARCH open label study of EDG-5506 in adults with Becker muscular dystrophy –


– Advancing Phase 2 trial of EDG-5506 in Becker muscular...
-Today at 08:03 am- MarketScreener

Related Keywords

United States , Denmark , Duchenne Becker , Kevin Koch , Facebook , Drug Administration , Research Row , Edgewise Therapeutics Inc , Linkedin , Nasdaq , Securities Exchange , Twitter , Exchange Commission , Edgewise Therapeutics , Chief Executive Officer , Month Topline Results , Label Study , First In Class Sarcomere Modulator , Muscular Dystrophy Patient , Parent Project Muscular Dystrophy , Annual Conference , Fast Track , Limb Girdle , Functional Changes , Becker Muscular Dystrophy , Clinical Trials , Scientific Reports , Selection Approach , Optimal Biomarker Using Quantitative Muscle , Functional Assessments , Securities Act , Securities Exchange Act , Markets ,